Selective internal radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.
The following indications will be considered:
- Primary liver cancer (hepatocellular carcinoma);
- Metastatic liver cancer.
Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of selective internal radiation therapy (SIRT):
- Bio-Rad (Bio-Rex, Aminex)
- BTG (TheraSphere)
- Sirtex (Sir-spheres)
- Terumo (QuiremScout, QuiremSpheres)
Table of content is not available at the moment. Report is still ongoing.
The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.Read more
On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).Read more
In late May 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0177 and 0074 with changes to be implemented not later than August 01, 2021. Five new procedure codes related to diagnostic imaging, ENT, breast reconstruction, and gynecology, and nine new diagnostic codes were introduced.Read more
The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.Read more
On May 17, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period January 20, 2021 - April 20, 2021). One new Clinical Commissioning Policy related to radiotherapy was added to the work program, and four new policies related to radiotherapy were published in the period from January 20, 2021, to April 20, 2021. Two policies related to heart valve procedures and extracorporeal treatment were discontinued.Read more